Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01325558
Other study ID # CA-ALT-836-02-10
Secondary ID
Status Completed
Phase Phase 1
First received March 9, 2011
Last updated July 13, 2016
Start date May 2011
Est. completion date February 2015

Study information

Verified date July 2016
Source Altor Bioscience Corporation
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors. The purpose of this study is to determine the maximum tolerated dose (MTD), and to assess the safety and pharmacokinetic profile of ALT-836 given with gemcitabine. The clinical benefit, progression-free survival and overall survival of study participants will also be assessed.


Description:

Tissue Factor (TF) is over-expressed in most cancer types. Results from many recent studies have suggested a key role for TF in the development of cancer-associated thrombosis, tumor growth, tumor angiogenesis, and tumor metastasis. ALT-836, a recombinant human-chimeric monoclonal antibody, is designed as a direct TF antagonist to block TF displayed by cancers and to inhibit cancer-associated venous thromboembolism, tumor growth, tumor angiogenesis and tumor metastasis. In numerous pre-clinical studies in laboratory animals, including non-human primates, ALT-836 exhibits potent anti-tumor, anti-thrombotic and anti-inflammatory activities with a remarkable safety profile. In humans, ALT-836, administered as a single bolus and monotherapy in patients with coronary artery disease (CAD) and acute lung injury/acute respiratory distress syndrome (ALI/ARDS), is safe and exhibits anti-coagulant and anti-inflammatory effects. A Phase II study using a multi-dose regimen of ALT-836 is being conducted in patients with ALI/ARDS. In the dose-escalation study described in this protocol, the investigators will assess the safety and determine the maximum tolerated dose (MTD) of ALT-836 in combination with gemcitabine in patients with advanced malignancies known to overexpress TF and in which venous thromboembolism is a major complication.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 2015
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed

- Locally advanced or metastatic non-hematologic malignancies

- Measureable

- Refractory to standard therapies or single agent gemcitabine is indicated as a standard treatment option

PRIOR/CONCURRENT THERAPY:

- No concurrent radiotherapy, chemotherapy, immunotherapy or other investigational agents

- Must have recovered from side effects of prior therapies

PATIENT CHARACTERISTICS:

Life expectancy

- > 12 weeks

Performance Status

- ECOG 0 or 1

Bone Marrow Reserve

- Absolute Neutrophil count (AGC/ANC) = 1,500/uL

- Platelets = 100,000/uL

- Hemoglobin > 9 g/dL

Renal Function

- Calculated Glomerular filtration rate (GFR) > 59mL/min/1.73M^2

Hepatic Function

- Total bilirubin = 1.5 X ULN

- AST, ALT, and ALP = 3 X ULN or = 5.0 x ULN, if liver metastasis exists

- PT INR = 1.5 X ULN

Cardiovascular

- No history of clinically significant vascular disease

- No New York Heart Association (NYHA) Class > II heart failure

Hematologic

- No history of bleeding disorders

- No evidence of bleeding diathesis or coagulopathy

- No presence of clinically significant hemoptysis or hematuria, presence of serious non-healing wound or ulceration, or signs of other bleeding

- No evidence of a tumor invasion of any major blood vessel

- No trauma with increased risk of life-threatening bleeding or history of severe head trauma or intracranial surgery within two months of study entry

Surgery/Procedures

- No major surgery or open biopsy within 28 days before drug infusion or evidence of active bleeding postoperatively

- No plan for any major surgery during treatment period

- No presence or requirement of an epidural catheter or lumbar puncture within 48 hours prior to each dose of study treatment

- No anticipation of receiving an epidural catheter or a lumbar puncture within 48 hours after each dose of study treatment

Excluded Medications or Treatment Regimens

- Unfractionated heparin of > 15,000 units/day within 8 hours prior to each dose of study treatment

- Low-molecular weight heparin at a higher dose than recommended for prophylactic used or required within 20 hours prior to each dose of study treatment

- Warfarin used or required within 48 hours prior to each dose of study treatment and the prothrombin time (INR) exceeded the upper limit of normal range

- Direct thrombin inhibitors or Xa inhibitors

- Acetylsalicylic acid used or required within 72 hours prior to each dose of study treatment

- Clopidogrel bisulfate used or required within 48 hours prior to each dose of study treatment

- Anticipated requirement for anti-platelet or anti-coagulant agents excluding non-aspirin NSAID within 48 hours following study treatment infusion

Other

- No active systemic infection requiring parenteral antibiotic therapy

- No history of or presence of a CNS disease

- No history of allergic reactions to compounds of similar chemical or biologic composition

- Not HIV positive

- No women who are pregnant or nursing

- A negative serum pregnancy test if female

- Patients, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study

- No history of significant renal, endocrinologic, metabolic, immunologic or hepatic disease

- No evidence of psychiatric illness/social situations

- Other illness that in the opinion of the investigator would exclude the patient from participating

- Must provide informed consent and HIPAA authorization and comply with protocol-specified procedures and follow-up evaluations

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
ALT-836 in combination with gemcitabine
Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.

Locations

Country Name City State
United States Emory University, Winship Cancer Institute Atlanta Georgia
United States Carolinas Hematology-Oncology Associates Charlotte North Carolina
United States University of Iowa Hospitals and Clinics Iowa City Iowa
United States University of Rochester Medical Center, James P. Wilmot Cancer Center Rochester New York

Sponsors (1)

Lead Sponsor Collaborator
Altor Bioscience Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) of ALT-836 in combination with gemcitabine 18 months Yes
Primary Safety Profile Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment 18 months Yes
Primary Clinical Benefit Number of participants with complete response, partial response or stable disease 18 months No
Primary Progression Free Survival Number of participants with 9-month, 12-month, 18-month, 24-month, 30-month or 36-month progression-free survival 36 months No
Secondary Overall Survival Number of participants with 9-month, 12-month, 18-month, 24-month, 30-month or 36-month overall survival 36 months No
Secondary Pharmacokinetics Area under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-836 18 months No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03671226 - Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center N/A
Completed NCT01973673 - Healthy Bones Study N/A
Completed NCT01876927 - Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer Phase 2
Terminated NCT03295942 - A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors Phase 1
Completed NCT03238027 - A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors Phase 1
Recruiting NCT04260802 - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Phase 1/Phase 2
Completed NCT02823652 - Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer N/A
Completed NCT02227082 - Olaparib and Radiotherapy in Inoperable Breast Cancer Phase 1
Recruiting NCT01871363 - Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer Phase 2
Completed NCT01847001 - Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Phase 2
Terminated NCT03170115 - Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer Phase 2
Recruiting NCT04749108 - Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma Phase 2/Phase 3
Terminated NCT01836432 - Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Phase 3
Recruiting NCT01675999 - Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer Phase 2
Completed NCT01333709 - Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma Phase 2
Withdrawn NCT03849742 - Ride to Care - Quality of Life With Transportation for RT N/A
Active, not recruiting NCT03856060 - Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits N/A
Completed NCT04186884 - Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
Recruiting NCT04112836 - Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
Not yet recruiting NCT03051152 - D1 Versus D2 Lymphadenectomy in High Risk Elderly With Gastric Adenocarcinoma N/A